Divi's Laboratories Limited (DIVISLAB) Price & Analysis

Compare

7 Followers

DIVISLAB Stock Chart & Stats

₹6603.05

-₹20.75(-0.35%)

At close: Jan 09 4:00 PM EST

₹6603.05

-₹20.75(-0.35%)

Day’s Range― - ―

52-Week Range₹4,941.70 - ₹7,077.70

Previous CloseN/A

Volume63.15K

Average Volume (3M)6.36K

Market Cap

₹1.70T

Enterprise Value₹1.67T

Total Cash (Recent Filing)₹35.27B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)68.7

Beta0.87

Next Earnings

May 25, 2026

EPS Estimate

25.33

Next Dividend Ex-DateN/A

Dividend Yield0.46%

Share Statistics

EPS (TTM)21.98

Shares Outstanding265,468,570

10 Day Avg. Volume6,055

30 Day Avg. Volume6,356

Financial Highlights & Ratios

PEG Ratio1.82

Price to Book (P/B)9.84

Price to Sales (P/S)15.74

P/FCF Ratio290.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)97.57

Revenue Forecast (FY)₹106.19B

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthVery low leverage and a high equity ratio provide financial flexibility to fund capex, absorb shocks, and pursue strategic opportunities. Strong ROE (14.6%) indicates effective use of shareholder capital, supporting durable creditworthiness and long-term investment capacity.

Profitability And Operational EfficiencyConsistently high and improving net margins reflect pricing power and efficient operations in API manufacturing. Sustainable profitability supports reinvestment in production and R&D, enabling continued competitiveness and resilience across multi-month planning horizons.

Diversified API Business ModelA mix of contract manufacturing, direct API sales, exports and strategic partnerships spreads customer and revenue risk. Combined with an R&D pipeline, this diversified model supports steady demand, repeat contracts and longer-term product-led growth across global markets.

Bears Say

Free Cash Flow VolatilityLarge swings in free cash flow reduce predictability of internally generated funds, complicating capital allocation and dividend planning. Even with strong operating cash flow coverage, inconsistent FCF can constrain durable funding for capex, M&A or shareholder returns.

Declining Gross MarginA material drop in gross margin over time suggests rising input costs, adverse mix shifts, or pricing pressure in APIs. If persistent, margin erosion can weaken the company’s ability to sustain high net margins, invest in R&D, and maintain competitive differentiation long term.

Modest Recent Revenue GrowthLow single-digit recent revenue growth points to market maturation or near-term demand headwinds. With limited top-line expansion, maintaining elevated profitability and investing for future product expansion becomes more challenging without clear new product wins or share gains.

Divi's Laboratories Limited News

Divi’s Laboratories Files SEBI Dematerialisation Compliance Certificate for December Quarter

An update from Divi’s Laboratories Limited ( ($IN:DIVISLAB) ) is now available. Divi’s Laboratories Limited has submitted to...

2M ago

Divi’s Laboratories to Close Trading Window Ahead of Q3 FY26 Results

Divi’s Laboratories Limited ( ($IN:DIVISLAB) ) has shared an announcement. Divi’s Laboratories Limited has announced that it will...

2M ago

Divi’s Laboratories Releases Unaudited Financial Results for September 2025

Divi’s Laboratories Limited ( ($IN:DIVISLAB) ) just unveiled an announcement. Divi’s Laboratories Limited announced the publication of its...

4M ago

Divi’s Laboratories Announces Trading Window Closure

Divi’s Laboratories Limited ( ($IN:DIVISLAB) ) just unveiled an announcement. Divi’s Laboratories Limited has announced the closure of...

5M ago

Divi’s Laboratories Releases Q1 FY2026 Earnings Call Transcript

Divi’s Laboratories Limited ( ($IN:DIVISLAB) ) has provided an announcement. Divi’s Laboratories Limited has released the transcript of...

7M ago

Divi’s Laboratories Reports Stable Q1 Financial Results for 2025

Divi’s Laboratories Limited ( ($IN:DIVISLAB) ) has shared an announcement. Divi’s Laboratories Limited has announced its unaudited financial...

7M ago

DIVISLAB FAQ

What was Divi's Laboratories Limited’s price range in the past 12 months?

Divi's Laboratories Limited lowest stock price was ₹4941.70 and its highest was ₹7077.70 in the past 12 months.

What is Divi's Laboratories Limited’s market cap?

Divi's Laboratories Limited’s market cap is ₹1.70T.

When is Divi's Laboratories Limited’s upcoming earnings report date?

Divi's Laboratories Limited’s upcoming earnings report date is May 25, 2026 which is in 85 days.

How were Divi's Laboratories Limited’s earnings last quarter?

Divi's Laboratories Limited released its earnings results on Feb 11, 2026. The company reported ₹21.98 earnings per share for the quarter, missing the consensus estimate of ₹23.173 by -₹1.193.

Is Divi's Laboratories Limited overvalued?

According to Wall Street analysts Divi's Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Divi's Laboratories Limited pay dividends?

Divi's Laboratories Limited pays a Annually dividend of ₹30 which represents an annual dividend yield of 0.46%. See more information on Divi's Laboratories Limited dividends here

What is Divi's Laboratories Limited’s EPS estimate?

Divi's Laboratories Limited’s EPS estimate is 25.33.

How many shares outstanding does Divi's Laboratories Limited have?

Divi's Laboratories Limited has 265,468,570 shares outstanding.

What happened to Divi's Laboratories Limited’s price movement after its last earnings report?

Divi's Laboratories Limited reported an EPS of ₹21.98 in its last earnings report, missing expectations of ₹23.173. Following the earnings report the stock price went up 4.889%.

Which hedge fund is a major shareholder of Divi's Laboratories Limited?

Currently, no hedge funds are holding shares in IN:DIVISLAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Divi's Laboratories Limited

Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and supplies a range of carotenoids, as well as markets vitamins to nutritional, pharma, food/beverage, and feed industries. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.